1.2 million clinicians.
One living network.

Patterns we observe

• Rising repeat engagement with residual-risk evidence signals that LDL control alone is no longer resolving the clinical question.
• Cross-navigation from obesity to heart-failure content exposes where cardiometabolic ownership is shifting between specialties.
• Revisits to patient-selection evidence reveal where enthusiasm for new therapies is colliding with implementation uncertainty.

Patterns we observe

• Repeat access to de-escalation evidence reveals that stopping treatment can generate more uncertainty than starting it.
• Rapid movement from trial results to bedside protocols shows which evidence clinicians are trying to operationalise immediately.
• Cross-specialty reading around organ support exposes where ownership of the deteriorating patient remains unresolved.

Patterns we observe

• Patients-clear versus patients-controlled content separates interest in efficacy from confidence in durable disease control.
• Repeat engagement with switch and rescue criteria reveals where expanding choice is increasing, rather than reducing, uncertainty.
• Cross-reading between skin and systemic-disease evidence identifies when dermatology decisions are becoming multi-specialty decisions.

Patterns we observe

• Engagement that moves from weight loss to treatment persistence signals a shift from initiation excitement to long-term management concern.
• Repeat reading on patient-selection thresholds reveals where expanding eligibility is creating practical uncertainty.
• Cross-navigation between obesity, renal and cardiovascular evidence maps which outcomes are redefining therapeutic value.

Patterns we observe

• Initial engagement after bispecific data releases concentrates on toxicity management, revealing where efficacy is outrunning operational confidence.
• Repeated navigation across CAR-T, bispecific and targeted-therapy content exposes sequencing as the real competitive battleground.
• Deep engagement with cytopenia-management evidence identifies where confidence in managing treatment may limit confidence in using it.

Patterns we observe

• Cross-navigation from metabolic-risk content to liver-disease evidence reveals which clinicians are beginning to connect obesity with MASH progression.
• Repeat engagement with non-invasive testing thresholds exposes where diagnosis is stalling before specialist referral.
• Revisits to treatment-eligibility evidence identify the boundary between interest in a new therapy and readiness to act.

Patterns we observe

• Repeat access to duration and de-escalation evidence signals that antimicrobial uncertainty often persists after treatment choice.
• Engagement spikes around resistance mechanisms reveal emerging concern before local protocols visibly change.
• Cross-specialty searches for prophylaxis guidance expose where responsibility for immunocompromised patients remains fragmented.

Patterns we observe

• Cross-navigation from renal protection to heart-failure evidence reveals when kidney specialists begin to adopt a cardiorenal treatment frame.
• Repeat engagement with initiation thresholds exposes hesitation in treating patients before conventional renal decline is visible.
• Persistent reading around hyperkalaemia management identifies where safety concerns may obstruct guideline-directed therapy.

Patterns we observe

• Repeat engagement with progression-independent activity signals growing uncertainty about what disease control should mean beyond relapse reduction.
• Cross-navigation from biomarker evidence to treatment-switch content reveals when monitoring data begins to challenge therapeutic confidence.
• Deep reading on patient-selection criteria identifies where high-efficacy treatment interest is constrained by risk tolerance.

Patterns we observe

• Replay and revisit patterns around subgroup data reveal which results are generating conviction beyond the headline endpoint.
• Cross-navigation from efficacy to adverse-event management identifies where clinical promise is meeting operational resistance.
• Repeated comparison of sequencing pathways exposes where a crowded market has created more choice but less decision clarity.

Patterns we observe

• Repeat engagement with durability evidence distinguishes excitement about visual gain from confidence that the gain can be sustained.
• Navigation from efficacy to injection-burden content reveals when treatment value is being judged through feasibility, not outcomes alone.
• Cross-reading between ocular and systemic evidence identifies where referral behaviour may reshape the treatment pathway.

Patterns we observe

• Repeat engagement with patient-selection evidence reveals where procedural innovation is expanding faster than confidence in whom to treat.
• Cross-navigation from imaging findings to conservative-management content exposes uncertainty at the intervention threshold.
• Revisits to return-to-function evidence show when recovery expectations matter more than procedural endpoints.

Patterns we observe

• Engagement shifts from efficacy to long-term safety as evidence moves from adolescent to younger-patient populations.
• Repeat access to transition-of-care content reveals where therapeutic continuity is most vulnerable.
• Cross-specialty navigation around rare presentations identifies where diagnostic ownership remains unclear.

Patterns we observe

• Repeat engagement with phenotype and biomarker evidence reveals where precision treatment is creating new classification uncertainty.
• Cross-navigation between pulmonology, oncology and radiology content identifies where incidental findings begin to alter referral pathways.
• Revisits to inhaler-switch evidence expose where device confidence may matter as much as molecule confidence.

Patterns we observe

• Repeat engagement with functional-outcome evidence signals that symptom reduction alone is not resolving the treatment-value question.
• Cross-navigation from efficacy to tolerability content reveals where persistence risk begins to outweigh expected benefit.
• Deep reading on treatment-resistant pathways identifies where clinicians are searching for a new decision point, not another option.

Patterns we observe

• Cross-specialty access to imaging criteria reveals where radiology is influencing treatment selection before referral is complete.
• Repeat engagement with incidental-finding pathways exposes diagnostic uncertainty that extends beyond image interpretation.
• Navigation from detection to response-assessment evidence identifies where imaging is moving from confirmation to therapeutic arbitration.

Patterns we observe

• Engagement with therapy-switching evidence increases before therapy-sequencing questions intensify.
• Repeat navigation between biomarker and treatment-response content reveals where precision ambition is meeting decision uncertainty.
• Cross-specialty reading around systemic manifestations exposes where disease ownership extends beyond rheumatology.

Patterns we observe

• Repeated comparison of surveillance and intervention evidence exposes where earlier detection is increasing decision complexity.
• Cross-navigation from biomarker results to treatment-selection content reveals when diagnostic confidence begins to shape therapeutic intent.
• Revisits to quality-of-life outcomes identify where functional trade-offs may outweigh efficacy differences.

Patterns we observe

• Repeat engagement with recurrence-risk evidence reveals where treatment success is being redefined beyond initial response.
• Cross-navigation between fertility, oncology and chronic-disease content exposes competing priorities within the same patient journey.
• Deep reading on patient-selection criteria identifies where innovation is ahead of pathway readiness.

Patterns we observe

• Repeat engagement with biologic-eligibility criteria reveals where phenotype complexity is delaying treatment confidence.
• Cross-navigation between allergy, pulmonology and dermatology evidence maps how type-2 inflammation is dissolving specialty boundaries.
• Revisits to step-down evidence expose uncertainty about when disease control is durable enough to reduce treatment.